We are a research and development firm focusing on bringing forward a medication for opioid use disorder. Our firm is developing a sustained-release, subcutaneous naltrexone implant that will deliver the drug for at least six months. Once approved, this will be the first new treatment for opioid use disorder to come on the market since 2006. Pre-clinical studies have shown that our product is safe and effective. Phase 1 human clinical studies are projected to begin in Q2 2023.